Lord'S Mark Industries Limited · BSE:LORDSMARK
Lord'S Mark Industries — H1 FY2026-27 Earnings Presentation
37 slides from Lord'S Mark Industries's earnings presentation, Nov 17, 2026
Slide 1: H1 FY 2026-27 Investor Presentation filing letter to BSE
Date: November 17, 2026 To, BSE Limited, Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai - 400 001. Scrip Code: 501261 Subject: H1 FY 2026-27 INVESTOR PRESENTATION. Dear Sir/ Madam, In accordance with the Regulation 30 read with schedule III of the Securities and Exchange Board of India
Slide 2: Lord's Mark Industries Limited
27 years legacy of excellence Listed on MedTech Bombay Stock Exchange Lord's Mark Industries Limited Renewal Healthcare Energy Innovating sustainable businesses with global vision 2
Slide 3: Investment Highlights
Investment Highlights Technology led innovation, strong execution, and long term opportunity Growth Platform IP & Regulatory strength Strong order pipeline High-margin Healthcare (IVD, 30+ registered brands, 139 ₹3,000+ Cr renewable energy order MedTech, Dialysis, Genomics) trademarks, exclusive IIT
Slide 4: 27 Years Journey: From Paper Trading to India's MedTech Conglomerate
ey: From Paper Trading to India's MedTech Conglomerate 27 Years Journey: From Paper Trading to India's MedTech Conglomerate A founder who started at age 21 and built a diversified, BSE-listed platform through strategic pivots — each unlocking a higher-margin, higher-impact business vertical. 1998 —
Slide 5: Lords Mark at Glance
Lords Mark at Glance The group has now Diversified to add High-growth Businesses to amplify Scale and Global Presence Since pecs 10 MesTech —_ Lord's Mark Industries Limited [ane Qa Eaeegy PE Tords Mark Microbiotech Pvt Ltd Renalyx Health Systems Pvt Lea ——— ee Ed Eo 35+ Products 45+State presence 2
Slide 6: Strategic Pillars
Strategic Pillars Vision → Mission → Approach → Execution Philosophy 1 Vision 2 Mission 3 Approach 4 Execution Philosophy Innovation First Develop differentiated, IP-led Identify High-Impact solutions addressing real-world Opportunities challenges. To become one of India's To make advanced healthcar
Slide 7: MD's Corner
MD’s Corner MD’s Corner From vision to diversified conglomerate 1998 Vision 2030 Founded Lords Mark at 21, • Become one of the fastest-growing while pursuing engineering. MedTech companies in India. Started as a modest paper trading venture • Expand presence in US, EU, and 2013 GCC markets. Diversif
Slide 8: Leadership - Board of Directors & Executive Management
rship - Board of Directors Executive Management Leadership - Board of Directors & Executive Management Experienced Leadership Driving Innovation, Governance & Sustainable Growth D Directors & Key Management MT VS NL VP Manav Teli Vinay Sarda Nipun Lodha Vignesh Poojari Director – IVD & Pathology Dir
Slide 9: Why Now?
Why Now? Why Now? Driving growth across high potential business verticals Healthcare Renewable Capital Markets ▪ 70% of Indian deaths trace to non- ▪ PM Surya Ghar: ₹75,000 Cr ▪ BSE listing achieved via NCLT- communicable disease budget for residential solar approved reverse merger ▪ 70–80% of medic
Slide 10: India's Healthcare Landscape
dia's Healthcare Landscape India's Healthcare Landscape 70% of Deaths Trace to Non-Communicable Disease 237Mn 213Mn Diabetic / Pre-diabetic At risk of heart attack 254Mn 315Mn General obesity Hypertension 10% 1 in 9 Chronic Kidney Disease Lifetime cancer risk risk ▪ 70% of medical decisions rely on
Slide 11: Massive Market Opportunity
ve Market Opportunity Massive Market Opportunity High-Growth Markets Across Every Lord's Mark Business Line Problem Market Size Lord's Mark Solution Diagnostics and dialysis remain Indian MedTech: $11Bn→$50Bn In-house manufactured IVD, slow, imported, expensive and (2022–30, 20.8% CAGR); Renalyx AI
Slide 12: Demand for Diagnostic Machine, Biochemistry Reagents
Demand for Diagnostic Machine, Biochemistry Reagents we 6 USD 74.90 Billion Om oh 4 USD 5108 Billion 2024 2032 2023 2027 Source: https://www.thehindubusinessline.com/companies/diagnostic-equipment-market-is-to-reach-close-to-6-billion-by-2027/article68043619.ece OPPORTUNITIES INEXPORT hina and Germa
Slide 13: Lord's Med - Integrated Healthcare Platform
Lord’s Med - Integrated Healthcare Platform Lord’s Med - Integrated Healthcare Platform One Connected Healthcare Ecosystem AI Preventive Patient Diagnostics Devices Genomics Hospitals Govt. Analysis Care Programs A patient's journey moves from first diagnostic contact through AI-assisted analysis, c
Slide 14: Innovation & Technology
Innovation Technology Innovation & Technology MedTech IP advantage: Flagship Innovations Renalyx AI Dialysis AI Breast Screening Oncodiagnoscope 85% owned subsidiary C-MET collaboration BARC collaboration Innovation Innovation Innovation Cloud-connected AI dialysis unit built Non-radiative, painless
Slide 15: Acquisition of Renalyx Health Systems Pvt Ltd
Lord's Acquisition of Renalyx Health Systems Pvt Ltd (Renalyx) Lords Mark Industries Ltd has acquired 85% stake in Renalyx Health Systems Private Limited, a medical equipment designing and manufacturing company in India XM 4 SSK KKK Zh | ra = India’s first indigenous Al based Dialysis Machine Build
Slide 16: Leadership - Renalyx
Leadership - Renalyx Lord's Dr. Shyam holds a doctorate in Real Time Embedded Systems, specialising in Parallel Computer Architecture from Indian Institute of Science (gold Medal) & has been with CG Smith, Ericsson, Tata Consultancy Services and as Director of Technology at Philips. He was instrumen
Slide 17: Sickle Cell Testing
jickle Cell Testing Without accurate lab-based confirmatory diagnostic tests, an accurate diagnosis for SCD cannot be made and may sometimes be misdiagnosed with anemia or other disorders. Also, results for the traditional method of testing take 10-1 ‘ This inevitably has big consequences on treatme
Slide 18: E-Smart Clinics - In Partnership with Dozee
E-Smart Clinics - In Partnership with Dozee Lords Mark Industries has partnered with Dozee, a company specializing in contactless remote patient monitoring and early warning systems, to advance healthcare solutions, particularly in public hospitals. This collaboration focuses on leveraging Dozee's t
Slide 19: Renewable Energy & LED
Renewable Energy Led Renewable Energy & Led A Government-Anchored Order Book ▪ Key GoI programmes: SAUBHAGYA (UPNEDA-UP, APDCL-Assam), Household Electrification (UPNEDA-UP), rural electrification of Bihar & Jharkhand via EESL ▪ Current secured order book of ~₹2,000 Cr from UPNEDA, BREDA, EESL, APDCL
Slide 20: Why We Win
Why We Win Why We Win Sustainable Competitive Advantages 1. Regulatory advantage 2. R&D & Patent advantage CDSCO single-roof licence for rapid tests, reagents and Exclusive technology transfers from IIT Bombay, BARC, analysers, plus ICMR, US FDA and CE approvals C-MET and BITS Pilani 3. Execution &
Slide 21: Go-To-Market Strategy
Lords Our 3 pronged Go-To-Market strategy will lead to es Export ‘ Hospitals & \ ‘ + Hospitals Markets 7 a Retail Clinics - 4 Ny \ _ Europe i eae «USA | ~ e/ India mT a ‘ + Program \ Execution \ Government Ne * Outright ANN Sales
Slide 22: Strategic Partnerships
c Partnerships Strategic Partnerships R&D and Distribution Power Through Institutional Alliances IIT Bombay BARC C-MET, Thrissur BITS Pilani Exclusive licence for point-of- Exclusive technology transfer AI-powered, radiation-free Multiplex PCR for Myeloid care smartphone Sickle Cell for Oncodiagnosc
Slide 23: Manufacturing & Quality
ality Manufacturing & Quality Advanced In-House Manufacturing & Quality Control ISO 13485 99.60% CDSCO & WHO-GMP certified production QC precision consistency Single-roof manufacturing licence ▪ Immunoassay kits & PCR diagnostic reagents ▪ In-house facility with single-roof production of rapid kits,
Slide 24: Recent Milestones Turning Approvals Into Revenue
Recent Milestones Turning Approvals Into Revenue Recent Milestones Turning Approvals Into Revenue Only India licence to manufacture ICMR approval for Sickle Cell and Approval to manufacture Rapid, Biochemistry, Serology & Genome Testing veterinary blood-testing machines Analyzer machines under one r
Slide 25: Global Expansion
Global Expansion Global Expansion Exporting Indian MedTech Innovation “This entry into the US market is a ▪ United States: Lords Mark secured a maiden $1,000,000 testament to innovation and order for Contactless Remote Patient Monitoring (RPM) and excellence. Our AI-powered and AI Early Warning Syst
Slide 26: Media Coverage
Lord's Media Coverage
Slide 27: Forbes India Sep 2024 coverage
Lord's hamesha eagle saath! Forbes India Sep 2024 DEDICATED TO BU
Slide 28: E-Smart Clinic media coverage
* Focusing on innovation, sustainability, and responsible strategie partnerships Lord's Mark Industries and Unnat Bharat’s E Smart Clinic brings healthcare to India's doorsteps, blessed by PM Modi X Lots ‘Lords Mark Indust & Unnat Bharat Take off E Smart Clinic Project Pan India with Inauguration of
Slide 29: Recent Media Coverage
Recent Media Coverage Recent Media Coverage
Slide 30: Lord's Mark Goes Global with USD 1M US MedTech Order
NN Lord's hamesha eagle saath! Lord's Mark Industries Goes Global with USD 1MUS MedTech Order Lords Mark Industries Limited, has made a strategic entry into the United States market by securing its first major order valued at approximately $1 million. The order includes Contactless Remote Patient Mo
Slide 31: ESG & Governance
ESG Governance Sustainable Impact With Institutional Governance ESG & Governance Sustainable Impact With Institutional Governance E Environmental S Social G Governance ▪ Targeting Net-Zero carbon ▪ Partnered with the Ministry of ▪ BSE-listed entity adhering to emissions across operations by Tribal A
Slide 32: Strong Financial Growth Outlook - FY25-FY29
ong Financial Growth outlook –FY25–FY29 Driven by Healthcare Renewable Businesses Strong Financial Growth outlook – FY25–FY29 Driven by Healthcare & Renewable Businesses Lords Mark Industries is forecast to deliver a 3.6x revenue expansion from ₹710 Cr in FY25 to ₹2,586 Cr by FY29, underpinned by ac
Slide 33: Business Mix & Value Creation FY25-FY29
Business Mix Value Creation FY25–FY29 Healthcare Expected to Become the Primary Growth Engine Business Mix & Value Creation FY25–FY29 Healthcare Expected to Become the Primary Growth Engine Lords Mark operates across four distinct business segments. IVD+MedTech is on track to become the single large
Slide 34: Growth Roadmap 2030
Growth Roadmap 2030 Growth Roadmap 2030 FY 2026–27 FY 2027–28 Listing on NSE Wholetime manufacturing unit for Medtech; Global footprint in association with our partners Reach 2,000 pathology labs and 1,000 Renal in EU, USA & GCC countries Full-fledged R&D Care Units; execute the IVD/MedTech team in
Slide 35: Investment Thesis
Investment Thesis Investment Thesis Why Lords Mark is Positioned to Create Long-Term Shareholder Value? • 27-Year Proven Legacy - Established operating history with a demonstrated ability to evolve across multiple business cycles and successfully enter high-growth industries. ▪ Market leadership in
Slide 36: Risks & Mitigation
Risks Mitigation Risks & Mitigation A Balanced View for Institutional Diligence Regulatory approval timelines Government payment cycles Risk: New device approvals (CDSCO/US FDA/CE) Risk: PSU/state receivables can be slower than can take years private commercial sales Mitigation: Track record of secu
Slide 37: Thank you
Thank you Thank you ▪ Investor Relations: ir@lordsmark.com • info@lordsmark.com ▪ Corporate website: www.lordsmark.com ▪ Headquarters: Mumbai, Maharashtra, India ▪ Equity ticker: Listed on Bombay Stock Exchange (BSE)
Lord's Mark Industries — H1 FY2026-27 Earnings Presentation on 6ix